Details

Published on Thursday, 27 November 2014 13:08

HybriScan participates in major Dutch program for cancer vesicle detection technologies

HybriScan Technologies participates in a recently awarded program of the Dutch Technology Foundation STW for extracellular cancer vesicle detection technologies. HybriScan Technologies will supply a HybriScan Raman Microscope that is integrated with a JEOL scanning electron microscope (SEM). Hybrican will assist University of Twente in related research as well.

 In the STW Perspective program ‘New Technology for Monitoring Cancer Therapy Through Extracellular Vesicle Identity’, innovative technologies will be developed for the detection and characterization of vesicles that are secreted by cells . Because they are very small (50-1000 nm), present techniques are inadequate for clinical vesicle detection, however vesicles do contain clinical information about, for example, cancer, allergies, vascular disorders, and autoimmune diseases.

In this Perspective program, that is initiated by AMC and Twente University, 22 companies and 10 research groups unite to develop technology for detection and analysis of vesicles originating from cancer cells. This is expected to lead to a more effective and customized treatment of cancer.

STW invests € 4 million in the new program ‘New Technology for Monitoring Cancer Therapy Through Extracellular Vesicle Identity’. In addition, the 22 companies invest € 1.8 million. This research proposal is in line with the top sector High Tech Systems & Materials, and has some overlap with the top sectors Life Sciences & Health, Agriculture & Food, and Water.

The initiators (AMC and Twente University) have joined forces with groups from Utrecht University, VU University, Erasmus Medical Center, Delft University of Technology and the University of Wageningen.